Full Enrollment Reached in Rusfertide Trial for PCV

  Clinical trials can provide immense insight into potential treatment options and patient outcomes. Currently, biopharmaceutical company Protagonist Therapeutics, Inc. ("Protagonist") is working to gain insight into the efficacy of…

Continue Reading Full Enrollment Reached in Rusfertide Trial for PCV

New Dosing Guidelines Available: Hizentra for CIDP

In a recent news release, biotherapeutics company CSL Behring shared that the company received FDA approval to update the Hizentra label for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Within…

Continue Reading New Dosing Guidelines Available: Hizentra for CIDP